CLINUVEL says it has met its recruitment target in its Phase 3 trial (CUV105) of SCENESSE (afamelanotide) in vitiligo, with more than 200 patients enrolled. …
CLINUVEL recruits 200 patients for Phase 3 vitiligo trial of SCENESSE
May 7, 2025 Australian Biotech
Latest Video
New Stories
-
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies
April 10, 2026 - - Australian Biotech -
Lower official co-payment but patients paying for more unsubsidised medicines
April 10, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 10 April
April 10, 2026 - - Podcast -
Is there any example of another review or inquiry taking this long?
April 10, 2026 - - Latest News -
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 - - Latest News -
A decade of readiness as AVITA medical expands burn response capability
April 9, 2026 - - Australian Biotech -
Moderna names Carolyn Tucek-Szabo to lead Australia and New Zealand operations
April 9, 2026 - - Latest News